Context: Consumption of medicinal mushrooms for disease prevention and maintaining healthhas a very long history in Asia. Grifola frondosa (Fr) S.F. Gray (GF) (Meripilaceae) is a medicinalfungus popularly used for enhancing immune systems, lowering blood glucose, and improvingspleen, stomach, and nerve functions.Objective: This study examines the hypoglycemic effects of GF in vitro and in vivo, and analyzesthe chemical profiles of its bioactive components.Materials and methods: In vitro hypoglycemic effects of GF was evaluated enzymaticallyusing a-amylase and a-glucosidase inhibition assays, whereas in vivo study was conducted onhigh-fat diet fed and streptozotocin (HFD + STZ)-induced hyperglycemic mice. GC-MS was usedto determine the chemical profiles of bioactive components.Results: The non-polar fraction of GF exhibited a stronger anti-a-glucosidase activity(IC50: 0.0332 mg/ml) than acarbose, but its anti-a-amylase activity (IC50: 0.671 mg/ml) wasweaker. Oral administration of GF at 600 mg/kg (GF600) significantly lowered the bloodglucose, HbA1c, average blood glucose, and serum total cholesterol levels in hyperglycemicmice. Although GF was found to contain mainly oleic acid and linoleic acid, their levels in thefungus were low, suggesting that the effects of GF on HFD + STZ-induced hyperglycemic micecould be due to factors other than these fatty acids.Conclusion: These results conclude that GF possesses anti-a-glucosidase activity, andhypoglycemic effect in HFD + STZ-induced hyperglycemic mice.
